Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.55 |
| ▸ | LIPE | Q05469 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114677 | 1.00 | EPHX2 (0.55) | EPHX2LIPEMAPTTP53SMN1; SMN2 | |
| SCHEMBL10114763 | 0.90 | ENPP3 (0.46) | EPHX2LIPEKMT2A | |
| SCHEMBL13523289 | 0.89 | EPHX2 (0.47) | EPHX2LIPEMAPTTP53SMN1; SMN2 | |
| SCHEMBL13204283 | 0.86 | HTT (0.58) | EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL10114008 | 0.86 | HTT (0.58) | EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL10133222 | 0.85 | NPY5R (0.56) | EPHX2LIPEMAPTTP53SMN1; SMN2 | |
| SCHEMBL10114314 | 0.85 | NPY5R (0.56) | EPHX2LIPEMAPTTP53SMN1; SMN2 | |
| SCHEMBL10114143 | 0.85 | NPY5R (0.53) | EPHX2MAPTMEN1KMT2A | |
| SCHEMBL12882810 | 0.85 | NPY5R (0.53) | EPHX2MAPTMEN1KMT2A | |
| SCHEMBL10114979 | 0.84 | KDR (0.50) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | EPHX2 2158/4885LIPE 1237/4885MAPT 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.